The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02011906

Enrollment

Registered

2013-12-13

Start date

2013-10-31

Completion date

2015-08-31

Last updated

2013-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

antioxidant enzymes, omega 3, vitamin E, CAD, Sirtuins, FOXOs

Brief summary

The aim of this study is to determine the effects of omega 3 supplementation and its concurrent supplementation with vitamin E on the serum levels of antioxidant enzymes and the expressions of the PGC-1a, h TERT, FOXO1, FOXO3a , SIRT1,SIRT3, SIRT6 genes in PBMC cells in the patients with coronary artery disease

Interventions

DIETARY_SUPPLEMENTomega 3

DIETARY_SUPPLEMENTvitamin E

DIETARY_SUPPLEMENTplacebo of omega 3

DIETARY_SUPPLEMENTplacebo of vitamin E

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

45 Years to 65 Years

Healthy volunteers

Inclusion criteria

\- literate, willingness to participation, CAD patients 45- 65 years old, body mass index\< 30, avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention, willing to maintain body weight during the study

Exclusion criteria

* people who have used vitamin E or omega 3 supplements in last 3 months, having chronic renal disease ,cancer, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism, diabetes, treatment with PPAR-gamma agonists or Thiazolidinediones, Smokers

Design outcomes

Primary

Measure	Time frame
serum total antioxidant capacity	change from baseline at 2 months
serum triglycerides level	change from baseline at 2 months
serum LDL cholesterol	change from baseline at 2 months
serum insulin	change from baseline at 2 months
serum Hs-CRP	change from baseline at 2 months
serum gluthatione peroxidase	change from baseline at 2 months
serum catalase	change from baseline at 2 months
serum superoxide dismutase	change from baseline at 2 months
serum total cholesterol	change from baseline at 2 months
serum HDL cholesterol	change from baseline at 2 months

Secondary

Measure	Time frame
gene expression of SIRT3	change from baseline at 2 months
gene expression of SIRT6	change from baseline at 2 months
gene expression of PGC-1a	change from baseline at 2 months
gene expression of FOXO3a	change from baseline at 2 months
gene expression of FOXO1	change from baseline at 2 months
gene expression of h TERT	change from baseline at 2 months
gene expression of SIRT1	change from baseline at 2 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026